Synthekine, Inc.

Genentech, Inc.

Genetech, Inc.

F. Hoffmann-La Roche Ag

Patrick J Lupardus

Deepti Rokkam

Robert Kastelein

Sandro Vivona

Gerald R Nakamura

Mercedesz Balazs

Nancy Chiang

Zhonghua Lin

Henry Chiu

Ning Chai

Min Xu

Hyunjoo Park

Mahesh Yadav

Yan Wu

Wei-Ching Liang

Lee R Swem

Dhaya Seshasayee

Meredith C Hazen

Jane Louise Grogan

Robert J Johnston

Ira Mellman

Jennie Lill

Lelia Delamarre

Suchit Jhunjhunwala

Joseph R Arron

Wendy Green Halpern

Jian Ping Yin

Thirumalai Rajan Ramalingam

Daryle Depianto

Tulika Tyagi

Zhaoyu Jin

Lee Swern

WeiYu Lin

Mahalakshmi Ramadass

Tianhe Sun

Jia Wu

Jane L Grogan

Meredith Hazen

Juan Zhang

Wyne P Lee

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human gp130, compositions comprising such antibodies, and methods of use thereof.

GP130 binding molecules and methods of use

The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.

Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL10Ra, compositions comprising such antibodies, and methods of use thereof.

IL10RA binding molecules and methods of use

Provided herein are IL12R binding molecules that bind to IL12Rb1 and IL12Rb2 and comprise an anti-IL12Rb2 sdAb and an anti-IL12Rb2 VH antibody.

IL12 receptor synthetic cytokines and methods of use

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL10Rb, compositions comprising such antibodies, and methods of use thereof.

IL10RB binding molecules and encoding nucleic acids

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of IL2Rb, compositions comprising such antibodies, and methods of use thereof.

IL2RB binding molecules and methods of use

Provided herein are IL27R binding proteins that bind to IL27Rα and gp130 and comprise an anti-IL27Rα VH antibody and an anti-gp130 VH antibody.

Compositions and methods related to IL27 receptor binding

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL27Rα, compositions comprising such antibodies, and methods of use thereof.

IL27RAlpha binding molecules and methods of use

Provided herein are IL10R binding molecules that bind to IL10Ra and IL10Rb and comprise an IL10Rb sdAb and an IL10Rb VHH antibody.

IL10 receptor binding molecules and methods of use

Provided herein are IFNGR binding molecules that bind to IFNGR1 and IFNGR2 and comprise an anti-IFNGR2 sdAb and an anti-IFNGR2 VH antibody.

IFNGR binding synthetic cytokines and methods of use

The present disclosure provides IL12 and IL23 muteins as partial agonists comprising modified human p40 molecules that associate with human p35 (hP35) and human P19 (hP19) to form modified hIL-12 and IL23 partial agonists wherein the individual components of IL12 and IL23 muteins are linked to engineered Fc domains.

Heterodimeric Fc cytokines and uses thereof

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL2Rg, compositions comprising such antibodies, and methods of use thereof.

IL2RG binding molecules and methods of use

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IFNgR2, compositions comprising such antibodies, and methods of use thereof.

Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL23R, compositions comprising such antibodies, and methods of use thereof. Further disclosed are sequences of complementarity determining regions (CDR1, CDR2 and CDR3) and polypeptide sequences of human and mouse sdAbs.

IL23R binding molecules and methods of use

The invention provides isoform-selective anti-TGFβ antibodies and methods of using the same. In particular, isoform-selective anti-TGFβ2, anti-TGFβ3, and anti-TGFβ2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGFβ-related disorders.

Growing community of inventors

Menlo Park, CA, United States of America

Patrick J Lupardus